Analysts Set Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Target Price at $8.00

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) has been given a consensus rating of "Hold" by the five research firms that are presently covering the stock, Marketbeat.com reports. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $8.00.

Several brokerages have weighed in on VRCA. Needham & Company LLC reissued a "hold" rating on shares of Verrica Pharmaceuticals in a report on Wednesday, May 14th. HC Wainwright reiterated a "neutral" rating on shares of Verrica Pharmaceuticals in a research note on Tuesday, April 8th. Finally, Wall Street Zen upgraded shares of Verrica Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd.

Verrica Pharmaceuticals Stock Down 7.6%

Shares of NASDAQ VRCA traded down $0.07 during midday trading on Friday, reaching $0.81. 445,279 shares of the company's stock traded hands, compared to its average volume of 629,260. Verrica Pharmaceuticals has a one year low of $0.38 and a one year high of $8.98. The stock's 50 day simple moving average is $0.61 and its 200-day simple moving average is $0.61. The company has a market cap of $74.60 million, a price-to-earnings ratio of -0.67 and a beta of 1.76.

Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.04. The firm had revenue of $3.44 million during the quarter, compared to the consensus estimate of $2.53 million. Equities analysts predict that Verrica Pharmaceuticals will post -1.46 EPS for the current fiscal year.

Hedge Funds Weigh In On Verrica Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Caligan Partners LP acquired a new stake in shares of Verrica Pharmaceuticals in the fourth quarter worth $5,201,000. Boothbay Fund Management LLC purchased a new position in shares of Verrica Pharmaceuticals during the 4th quarter valued at about $1,811,000. Sovran Advisors LLC lifted its holdings in shares of Verrica Pharmaceuticals by 91.3% in the 2nd quarter. Sovran Advisors LLC now owns 750,391 shares of the company's stock valued at $398,000 after buying an additional 358,228 shares during the period. Geode Capital Management LLC boosted its stake in shares of Verrica Pharmaceuticals by 4.8% in the fourth quarter. Geode Capital Management LLC now owns 477,269 shares of the company's stock worth $334,000 after buying an additional 21,789 shares during the last quarter. Finally, Heights Capital Management Inc. purchased a new stake in shares of Verrica Pharmaceuticals in the fourth quarter worth about $246,000. 42.45% of the stock is owned by hedge funds and other institutional investors.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.